Ingalls & Snyder LLC Grows Position in Novartis AG (NYSE:NVS)
Ingalls & Snyder LLC Grows Position in Novartis AG (NYSE:NVS)
Ingalls & Snyder LLC raised its holdings in Novartis AG (NYSE:NVS – Get Rating) by 7.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 105,098 shares of the company's stock after acquiring an additional 6,961 shares during the period. Ingalls & Snyder LLC's holdings in Novartis were worth $9,222,000 at the end of the most recent reporting period.
英格爾斯-斯奈德有限責任公司在提交給美國證券交易委員會的最新文件中稱，今年第一季度，該公司將其在諾華製藥的持股比例提高了7.1%。該機構投資者持有105,098股該公司股票，在此期間又購買了6,961股。在最近一次報告期結束時，Ingalls&Snyder LLC持有的諾華股份價值9,222,000美元。
Several other institutional investors and hedge funds have also recently modified their holdings of the business. Dimensional Fund Advisors LP increased its position in shares of Novartis by 35.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,870,136 shares of the company's stock valued at $338,521,000 after purchasing an additional 1,003,235 shares during the last quarter. Cullen Capital Management LLC increased its position in shares of Novartis by 17.6% during the 1st quarter. Cullen Capital Management LLC now owns 3,295,271 shares of the company's stock valued at $289,160,000 after purchasing an additional 492,643 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Novartis by 4.7% during the 1st quarter. Fisher Asset Management LLC now owns 10,871,033 shares of the company's stock valued at $953,933,000 after purchasing an additional 486,367 shares during the last quarter. Renaissance Technologies LLC grew its position in Novartis by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 3,727,570 shares of the company's stock worth $326,051,000 after acquiring an additional 420,333 shares during the last quarter. Finally, Boston Partners grew its position in Novartis by 6.7% during the 4th quarter. Boston Partners now owns 4,677,403 shares of the company's stock worth $409,194,000 after acquiring an additional 292,854 shares during the last quarter. Hedge funds and other institutional investors own 9.40% of the company's stock.
其他幾家機構投資者和對衝基金最近也調整了對該公司的持股。Dimension Fund Advisors LP在第四季度將其在諾華股票的持倉增加了35.0%。Dimension Fund Advisors LP現在擁有3870,136股該公司的股票，價值338,521,000美元，在上個季度又購買了1,003,235股。第一季度，庫倫資本管理公司將其在諾華公司股票的持倉增加了17.6%。卡倫資本管理有限責任公司在上個季度額外購買了492,643股後，現在擁有3,295,271股該公司的股票，價值289,160,000美元。Fisher Asset Management LLC在第一季度將其在諾華股票的持倉增加了4.7%。Fisher Asset Management LLC在上個季度額外購買了486,367股後，現在擁有10,871,033股該公司股票，價值953,933,000美元。復興技術有限責任公司在第四季度將其在諾華的頭寸增加了12.7%。復興科技有限責任公司在上個季度增持了420,333股後，現在擁有3,727,570股該公司股票，價值326,051,000美元。最後，波士頓合夥公司在第四季度將其在諾華的頭寸增加了6.7%。波士頓合夥公司在上個季度增持了292,854股後，現在持有4677,403股該公司股票，價值409,194,000美元。對衝基金和其他機構投資者持有該公司9.40%的股份。
Analyst Ratings Changes
分析師評級發生變化
NVS has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reduced their price target on Novartis from CHF 80 to CHF 75 in a research report on Wednesday, June 29th. Barclays raised their price target on Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. upgraded Novartis from a "hold" rating to a "buy" rating in a research report on Thursday, April 14th. UBS Group raised their price target on Novartis from CHF 85 to CHF 88 and gave the stock a "neutral" rating in a research report on Wednesday, April 27th. Finally, Oppenheimer lowered Novartis from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $87.33.
NVS一直是最近幾份研究報告的主題。德意志銀行Aktiengesellschaft在6月29日星期三的一份研究報告中將諾華的目標價從80瑞士法郎下調至75瑞士法郎。巴克萊在4月14日週四的一份研究報告中將諾華的目標價從80瑞士法郎上調至85瑞士法郎。在4月14日週四的一份研究報告中，將諾華的評級從持有上調至買入。瑞銀集團在4月27日週三的一份研究報告中將諾華公司的目標價從85瑞士法郎上調至88瑞士法郎，並給予該股“中性”評級。最後，在6月3日星期五的一份研究報告中，奧本海默將諾華的評級從“跑贏大盤”下調至“市場表現”。兩名投資分析師對該股的評級為賣出，八名分析師發佈了持有評級，三名分析師給予了買入評級，一名分析師對該股給予了強烈的買入評級。根據MarketBeat.com的數據，該股目前的平均評級為持有，共識目標價為87.33美元。
Novartis Trading Up 0.4 %
諾華公司股價上漲0.4%
Novartis (NYSE:NVS – Get Rating) last released its earnings results on Monday, July 18th. The company reported $1.56 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.04. The company had revenue of $12.78 billion during the quarter, compared to analysts' expectations of $12.78 billion. Novartis had a return on equity of 21.88% and a net margin of 44.31%. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS. Equities research analysts predict that Novartis AG will post 6.06 earnings per share for the current fiscal year.
諾華公司(紐約證券交易所代碼：NVS-GET Rating)最近一次發佈收益報告是在7月18日星期一。該公司公佈本季度每股收益為1.56美元，比分析師普遍預期的1.52美元高出0.04美元。該公司當季營收為127.8億美元，高於分析師預期的127.8億美元。諾華的股本回報率為21.88%，淨利潤率為44.31%。與去年同期相比，該公司本季度的收入下降了1.4%。去年同一季度，該業務公佈的每股收益為1.64美元。股票研究分析師預測，諾華製藥本財年每股收益將達到6.06歐元。
About Novartis
諾華公司簡介
(Get Rating)
(獲取評級)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
諾華製藥在全球研究、開發、製造和營銷保健品。該公司通過兩個部門運營，創新藥品和Sandoz。創新藥品部門為患者和醫療保健提供者提供處方藥。它還提供眼科、神經科學、免疫學、肝科、皮膚科、呼吸科、心血管、腎臟和新陳代謝藥物產品。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免費獲取StockNews.com關於諾華(Novartis)的研究報告
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- Beyond Meat不是沒有希望，而且它很便宜
- 蘋果為何可能在年底創下歷史新高
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受諾華日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對諾華和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。